Who are Levoxyl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytomel, L-thyroxine (L-T4), Thyroid hormone, Tirosint®-SOL, Levothyroxin-Na, Armour Thyroid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levoxyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Levoxyl — Competitive Intelligence Brief

Levoxyl (Levothyroxine Sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone replacement. Area: Oncology.

marketed Thyroid hormone replacement Thyroid receptor proteins attached to DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Levoxyl (Levothyroxine Sodium) — Pfizer Inc.. Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levoxyl TARGET	Levothyroxine Sodium	Pfizer Inc.	marketed	Thyroid hormone replacement	Thyroid receptor proteins attached to DNA
Cytomel	Liothyronine Sodium	Pfizer Inc.	marketed	Thyroid hormone replacement	Thyroid receptor proteins attached to DNA
L-thyroxine (L-T4)	L-thyroxine (L-T4)	Oregon Health and Science University	marketed	Thyroid hormone replacement	Thyroid hormone receptor (TR-alpha, TR-beta)
Thyroid hormone	Thyroid hormone	Merck Sharp & Dohme LLC	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha, TR-beta)
Tirosint®-SOL	Tirosint®-SOL	IBSA Institut Biochimique SA	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha and TR-beta)
Levothyroxin-Na	Levothyroxin-Na	Sanofi	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha and TR-beta)
Armour Thyroid	Armour Thyroid	AbbVie	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha and TR-beta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone replacement class)

Pfizer Inc. · 2 drugs in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
M. Medici · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Meyer Children's Hospital IRCCS · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sanofi · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levoxyl — Competitive Intelligence Brief. https://druglandscape.com/ci/levoxyl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab